Celldex Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 2.9, 13.05, 166.23, 507.13, 963.5 ], "ebit_estimate": [ -344.59, -375.58, -267.6, -8.19, 472.22 ], "ebitda_estimate": [ -343.65, -382.29, -250.92, null, null ], "net_income_estimate": [ -322.13, -359.39, -262.11, -6.98, 382.32 ], "per_share_eps_estimate": [ -4.34, -4.47, -2.99, 0.05, 4.41 ], "eps_nri_estimate": [ -4.36, -4.38, -2.99, -0.21, 4.01 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 7.35, 7.23, 5.97, null, null ], "pretax_income_estimate": [ -328.44, -367.24, -268.86, 65.68, 443.62 ], "operating_cash_flow_per_share_estimate": [ -4.38, -4.04, -2.05, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -58.88, -57.13, -37.36, null, null ], "gross_margin_estimate": [ 100, 90, 83.4, 85.25, 85.25 ], "operating_cash_flow_estimate": [ -291.56, -268.93, -136.46, null, null ], "pettm_estimate": [ 0, 0, 0, 798.16, 8.87 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "373.03", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 373.03, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -8.28, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -6.29, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 0.95, 1.04, 1.33, 0.88, 0.88, 0.88, 0.88 ], "ebit_estimate": [ -85.05, -85.97, -87.04, -86.78, -88.28, -93.75, -101.38 ], "ebitda_estimate": [ -83.18, -85.95, -89.48, null, null, null, null ], "net_income_estimate": [ -81.21, -82.46, -84.55, -82.18, -83.88, -89.89, -98.08 ], "per_share_eps_estimate": [ -1.07, -1.07, -1.06, -0.95, -0.97, -1.03, -1.11 ], "eps_nri_estimate": [ -1.06, -1.07, -1.07, -0.95, -0.97, -1.03, -1.11 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -82.69, -102.15, -85.45, -82.18, -83.88, -29.89, -98.08 ], "operating_cash_flow_per_share_estimate": [ -1.07, -1.05, -1.1, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, 100, 100, 100, 100 ], "operating_cash_flow_estimate": [ -71.23, -69.89, -73.22, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "373.03", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 373.03, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -8.28, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -6.29, "future_operating_cash_flow_per_share_estimate_growth": null }